EE03178B1 - Kondenseerunud bitsüklilist tuuma sisaldavad ühendid, nende vaheproduktid, valmistamismeetodid ja farmatseutilised kompositsioonid - Google Patents

Kondenseerunud bitsüklilist tuuma sisaldavad ühendid, nende vaheproduktid, valmistamismeetodid ja farmatseutilised kompositsioonid

Info

Publication number
EE03178B1
EE03178B1 EE9400106A EE9400106A EE03178B1 EE 03178 B1 EE03178 B1 EE 03178B1 EE 9400106 A EE9400106 A EE 9400106A EE 9400106 A EE9400106 A EE 9400106A EE 03178 B1 EE03178 B1 EE 03178B1
Authority
EE
Estonia
Prior art keywords
intermediates
preparation
methods
pharmaceutical compositions
bicyclic ring
Prior art date
Application number
EE9400106A
Other languages
English (en)
Inventor
A. Robl Jeffrey
R. Kronenthal David
D. Godfrey Jollie Jr.
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of EE03178B1 publication Critical patent/EE03178B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/30—Preparation of optical isomers
    • C07C227/32—Preparation of optical isomers by stereospecific synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/02—Preparation of sulfones; Preparation of sulfoxides by formation of sulfone or sulfoxide groups by oxidation of sulfides, or by formation of sulfone groups by oxidation of sulfoxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C07C327/34—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups with amino groups bound to the same hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Steroid Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
  • Dram (AREA)
  • Reduction Or Emphasis Of Bandwidth Of Signals (AREA)
  • Peptides Or Proteins (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
EE9400106A 1993-06-15 1994-10-31 Kondenseerunud bitsüklilist tuuma sisaldavad ühendid, nende vaheproduktid, valmistamismeetodid ja farmatseutilised kompositsioonid EE03178B1 (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7797893A 1993-06-15 1993-06-15

Publications (1)

Publication Number Publication Date
EE03178B1 true EE03178B1 (et) 1999-04-15

Family

ID=22141128

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9400106A EE03178B1 (et) 1993-06-15 1994-10-31 Kondenseerunud bitsüklilist tuuma sisaldavad ühendid, nende vaheproduktid, valmistamismeetodid ja farmatseutilised kompositsioonid

Country Status (38)

Country Link
US (5) US5508272A (et)
EP (1) EP0629627B1 (et)
JP (1) JP3569550B2 (et)
KR (1) KR100395604B1 (et)
CN (1) CN1046525C (et)
AT (1) ATE266032T1 (et)
AU (1) AU672899B2 (et)
BG (1) BG62139B1 (et)
BR (1) BR1100970A (et)
CA (1) CA2124375C (et)
CY (1) CY2492B1 (et)
CZ (1) CZ289488B6 (et)
DE (1) DE69433752T2 (et)
DK (1) DK0629627T3 (et)
EE (1) EE03178B1 (et)
EG (1) EG20537A (et)
ES (1) ES2219644T3 (et)
FI (3) FI106464B (et)
GE (1) GEP19981301B (et)
HK (1) HK1001814A1 (et)
HU (1) HU216791B (et)
IL (2) IL109924A (et)
LT (1) LT3626B (et)
LV (1) LV10622B (et)
MY (1) MY123673A (et)
NO (1) NO306405B1 (et)
NZ (1) NZ260736A (et)
PH (1) PH30830A (et)
PL (1) PL178469B1 (et)
PT (1) PT629627E (et)
RO (1) RO112870B1 (et)
RU (1) RU2125056C1 (et)
SG (1) SG46510A1 (et)
SK (1) SK282529B6 (et)
TW (1) TW329423B (et)
UA (1) UA39924C2 (et)
UY (1) UY23787A1 (et)
ZA (1) ZA944163B (et)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552397A (en) * 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
US5504080A (en) * 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
US5654294A (en) * 1993-05-13 1997-08-05 Bristol-Myers Squibb Spiro lactam dual action inhibitors
CN1110865A (zh) * 1993-06-11 1995-10-25 卫材株式会社 氨基酸衍生物
US5508272A (en) * 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
US5525723A (en) * 1993-11-18 1996-06-11 Bristol-Myers Squibb Co. Compounds containing a fused multiple ring lactam
US5587375A (en) * 1995-02-17 1996-12-24 Bristol-Myers Squibb Company Azepinone compounds useful in the inhibition of ACE and NEP
US5877313A (en) 1995-05-17 1999-03-02 Bristol-Myers Squibb Benzo-fused azepinone and piperidinone compounds useful in the inhibition of ACE and NEP
US5635504A (en) * 1995-06-07 1997-06-03 Bristol-Myers Squibb Co. Diazepine containing dual action inhibitors
US5650408A (en) * 1995-06-07 1997-07-22 Karanewsky; Donald S. Thiazolo benzazepine containing dual action inhibitors
US6777550B1 (en) 1996-04-12 2004-08-17 Bristol-Myers Squibb Company N-formyl hydroxylamine containing compounds useful as ACE inhibitors and/or NEP inhibitors
AU748824B2 (en) 1997-03-14 2002-06-13 Basf Aktiengesellschaft Cycloalkylalkanecarboxamides and the production and use thereof
US6133002A (en) 1997-09-25 2000-10-17 Dsm N.V. Process for preparing optically active 2-amino-ω-oxoalkanoic acid derivatives
US6340752B1 (en) 1998-01-06 2002-01-22 Bristol-Myers Squibb Co. Deprotection and recrystallization processes
IT1298268B1 (it) * 1998-02-18 1999-12-20 Zambon Spa Procedimento per la preparazione dell'acido (s)-2-bromo-3-fenil- propionico
IT1298267B1 (it) * 1998-02-18 1999-12-20 Zambon Spa Procedimento per la preparazione dell'acido (s)-2-acetiltio-3-fenil- propionico e dei suoi sali
WO1999065500A1 (en) 1998-06-17 1999-12-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
DE69939190D1 (de) * 1998-06-18 2008-09-04 Hoffmann La Roche Verfahren für Arylalkylsulfid
US6174711B1 (en) 1998-07-05 2001-01-16 Mitsubishi Gas Chemical Company Method for producing L-allysine acetal
US6162913A (en) * 1998-07-15 2000-12-19 Bristol-Myers Squibb Co. Preparation of [4S-(4α,7α,10aβ)]-4-amino-octahydro-5-oxo-7H-pyrido[2,1 -b] [1,3]thiazepine-7-carboxylic acid, methyl ester and salts thereof via novel disulfides
EP1097236A4 (en) * 1998-07-15 2006-10-04 Bristol Myers Squibb Co STEREOSELECTIVE REDUCING AMINATION OF KETONES
US6468781B1 (en) 1999-07-08 2002-10-22 Bristol-Myers Squibb Company Stereoselective reductive amination of ketones
KR20010071895A (ko) * 1998-07-15 2001-07-31 스티븐 비. 데이비스 신규 디옥솔란을 통한 (ｓ)-2-아미노-6,6-디메톡시헥산산메틸 에스테르의 제조 방법
CA2342792A1 (en) 1998-09-03 2000-03-16 Bristol-Myers Squibb Company Enzymatic oxidative deamination process
ES2237970T3 (es) 1998-11-11 2005-08-01 Novartis Ag Produccion de 2-amino-2-(2-(4-alquil c2-20-fenil)etil)propano-1,3-dioles.
RU2245147C2 (ru) * 1999-03-29 2005-01-27 Бристол-Маерс Сквибб Компани Применение ингибитора вазопептидазы для лечения стенокардии
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
DE60022525T2 (de) * 1999-08-30 2006-06-14 Sanofi Aventis Deutschland Ramipril zur vorbeugung von kardiovaskulären vorfällen
US6300503B1 (en) 1999-12-17 2001-10-09 Dixie Chemical Company Hydantoin intermediates for the synthesis of omapatrilat and methods for producing and using the same
NL1014353C2 (nl) * 2000-02-11 2001-08-15 Dsm Nv Werkwijze voor de bereiding van (R) -2-broom-3-fenylpropaanzuur.
NL1014354C2 (nl) * 2000-02-11 2001-08-14 Dsm Nv Werkwijze voor de bereiding van (S) -2-acethylthio-3-fenylpropaanzuur.
US6509330B2 (en) 2000-02-17 2003-01-21 Bristol-Myers Squibb Company Hydroxamic acid containing compounds useful as ACE inhibitors and/or NEP inhibotors
ATE275129T1 (de) 2000-03-30 2004-09-15 Ajinomoto Kk Verfahren zur herstellung von aromatischen acylthiocarbonsäurederivaten
US6620600B2 (en) * 2000-09-15 2003-09-16 Bristol-Myers Squibb Co. Enzymatic resolution of aryl and thio-substituted acids
US7388098B2 (en) 2000-09-29 2008-06-17 Bristol-Myers Squibb Company Dynamic resolution of isomers and resolved isomers
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US7119188B2 (en) * 2001-01-04 2006-10-10 Bristol-Myers Squibb Company N-carbobenzyloxy (N-CBZ)-deprotecting enzyme and uses therefor
US6828119B2 (en) * 2001-01-04 2004-12-07 Bristol Myers Squibb Company Enzymatic deprotection of amines and hydroxides
AU2002365132A1 (en) * 2001-10-17 2003-07-15 Bristol-Myers Squibb Company BICYCLIC LACTAM DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-Alpha CONVERTING ENZYME (TACE)
US7107198B2 (en) * 2001-11-02 2006-09-12 Sun Microsystems, Inc. Automatic generation of reduced-size circuit models including inductive interaction
US6984645B2 (en) 2001-11-16 2006-01-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
AU2002357290A1 (en) * 2001-12-20 2003-07-09 Bristol-Myers Squibb Company Administration of vasopeptidase inhibitors to reduce pulse pressure
US20070197552A1 (en) * 2002-01-11 2007-08-23 Novo Nordisk A/S Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
ATE409466T1 (de) * 2002-01-11 2008-10-15 Novo Nordisk As Verfahren und zusammensetzung zur behandlung von diabetes, hypertonie, chronischer herzinsuffizienz und mit flüssigkeitsretention einhergehenden zuständen
EP1383042B1 (en) * 2002-07-19 2007-03-28 STMicroelectronics S.r.l. A multiphase synchronous pipeline structure
US6842358B2 (en) * 2002-08-01 2005-01-11 Netlogic Microsystems, Inc. Content addressable memory with cascaded array
US7045653B2 (en) * 2002-12-23 2006-05-16 Pfizer, Inc. Pharmaceuticals
CL2004000544A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
US7273881B2 (en) 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
EP1729749A2 (en) 2004-03-17 2006-12-13 Novartis AG Use of renin inhibitors in therapy
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
CA2614664A1 (en) * 2005-07-14 2007-01-25 Franco Folli Daily dosage regimen for treating diabetes, obesity,metabolic syndrome and polycystic ovary syndrome
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US7390789B2 (en) * 2005-09-13 2008-06-24 William H Simmons Thio-containing inhibitors of aminopeptidase P, and compositions thereof
US7400236B2 (en) 2005-10-21 2008-07-15 Gm Global Technology Operations, Inc. Vehicular lane monitoring system utilizing front and rear cameras
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US8202902B2 (en) 2006-05-05 2012-06-19 The Regents Of The University Of Michigan Bivalent SMAC mimetics and the uses thereof
NZ572531A (en) * 2006-05-05 2011-09-30 Univ Michigan Bivalent smac mimetics and the uses thereof
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
AU2007276433B2 (en) 2006-07-20 2011-06-16 Novartis Ag Amino-piperidine derivatives as CETP inhibitors
JP2010508358A (ja) 2006-11-01 2010-03-18 ブリストル−マイヤーズ スクイブ カンパニー グルココルチコイド受容体、ＡＰ−１、および／またはＮＦ−κＢ活性の調節剤、並びにその使用
WO2008057862A2 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
EP2089389A2 (en) 2006-11-01 2009-08-19 Bristol-Myers Squibb Company Heterocyclic compounds as modulators of glucocorticoid receptor, ap-1, and/or nf-kappa-b activity
TW200838501A (en) * 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EA020466B1 (ru) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
TWI406850B (zh) 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
JP2010538071A (ja) 2007-09-07 2010-12-09 セラヴァンス， インコーポレーテッド 二重作用性降圧剤
WO2009059943A1 (en) 2007-11-05 2009-05-14 Novartis Ag 4-benzylamino-1-carboxyacyl-piperidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
CA2707651A1 (en) 2007-12-03 2009-06-11 Novartis Ag 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis
CA2705921A1 (en) 2007-12-11 2009-06-18 Theravance, Inc. Dual-acting benzoimidazole derivatives and their use as antihypertensive agents
AU2008350907A1 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
WO2009134741A1 (en) 2008-04-29 2009-11-05 Theravance, Inc. Dual-acting antihypertensive agents
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011525537A (ja) 2008-06-24 2011-09-22 ブリストル−マイヤーズ スクイブ カンパニー グルココルチコイド受容体、ＡＰ−１、および／またはＮＦ−κＢ活性のシクロペンタチオフェン調節剤およびその使用
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010011821A2 (en) 2008-07-24 2010-01-28 Theravance, Inc. Dual-acting antihypertensive agents
SI2429995T1 (sl) 2009-05-15 2014-05-30 Novartis Ag Arilpiridini kot inhibitorji aldosteron sintaze
BRPI1012852A2 (pt) 2009-05-15 2018-06-19 Novartis Ag derivados de benzoxazolona como inibidores da sintase de aldoesterona
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
WO2011005674A1 (en) 2009-07-07 2011-01-13 Theravance, Inc. Dual-acting pyrazole antihypertensive agents
US8372984B2 (en) 2009-07-22 2013-02-12 Theravance, Inc. Dual-acting oxazole antihypertensive agents
EP2993169B1 (en) 2009-11-17 2017-12-20 Novartis AG Aryl-pyridine derivatives as aldosterone synthase inhibitors
US8575160B2 (en) 2009-11-30 2013-11-05 Novartis Ag Imidazole derivatives as aldosterone synthase inhibitors
EP2526095A1 (en) 2010-01-19 2012-11-28 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
WO2011116115A1 (en) 2010-03-16 2011-09-22 Novartis Ag Aliskiren composition comprising a medium chain fatty acid, their process of manufacturing
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8993631B2 (en) * 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
JP5944922B2 (ja) 2010-12-15 2016-07-05 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤
CA2817368C (en) 2010-12-15 2019-12-31 Theravance, Inc. Neprilysin inhibitors
KR101854874B1 (ko) 2011-02-17 2018-05-04 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 네프릴리신 억제제로서 치환된 아미노부티릭 유도체
JP5959066B2 (ja) 2011-02-17 2016-08-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤としての置換アミノ酪酸誘導体
JP5885832B2 (ja) 2011-05-31 2016-03-16 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤
EP2714662B1 (en) 2011-05-31 2017-10-11 Theravance Biopharma R&D IP, LLC Neprilysin inhibitors
CA2835220A1 (en) 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
TWI560172B (en) 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
US9045443B2 (en) 2012-05-31 2015-06-02 Theravance Biopharma R&D Ip, Llc Nitric oxide donor neprilysin inhibitors
ME02698B (me) 2012-06-08 2017-10-20 Theravance Biopharma R&D Ip Llc Inhibitori neprilizina
CA2873328A1 (en) 2012-06-08 2013-12-12 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
PT2882716T (pt) 2012-08-08 2017-03-13 Theravance Biopharma R&D Ip Llc Inibidores da neprilisina
WO2014085489A1 (en) 2012-11-30 2014-06-05 Sanford-Burnham Medical Research Institute Inhibitor of apoptosis protein (iap) antagonists
HUE034210T2 (hu) 2013-03-05 2018-02-28 Theravance Biopharma R&D Ip Llc Neprilizininhibitorok
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CN113388007A (zh) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015027021A1 (en) 2013-08-22 2015-02-26 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
CA2934898A1 (en) 2014-01-30 2015-08-06 Theravance Biopharma R&D Ip, Llc 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
AU2015210983B2 (en) 2014-01-30 2018-10-04 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
US9969988B2 (en) 2014-01-31 2018-05-15 Api Corporation Pipecolinic acid 4-hydroxylase and method for producing 4-hydroxy amino acid using same
CA2950911C (en) 2014-06-04 2023-10-10 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
US9212206B1 (en) 2014-11-24 2015-12-15 William H Simmons 4-Fluoro-Thio-containing inhibitors of APP2, compositions thereof and method of use
KR102640906B1 (ko) 2015-02-11 2024-02-27 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 네프릴리신 저해제로서 (2s,4r)-5-(5''-클로로-2''-플루오로비페닐-4-일)-4-(에톡시옥살릴아미노)-2-히드록시메틸-2-메틸펜타노익산
US9533962B2 (en) 2015-02-19 2017-01-03 Theravance Biopharma R&D Ip, Llc (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
DK3408260T3 (da) 2016-03-08 2021-08-02 Theravance Biopharma R&D Ip Llc Krystallinsk (2s,4r)-5-(5'-chlor-2-fluor-[1,1'-biphenyl]-4-yl)-2-(ethoxy¬methyl)-4-(3-hydroxyisoxazol-5-carboxamido)-2-methylpentansyre og anvendelser deraf

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT20991B (de) 1903-12-22 1905-08-10 Duplex Radiator Company Heizkörper für Gas- und Petroleumöfen.
AT198791B (de) 1950-12-20 1958-07-25 Westinghouse Air Brake Co Steuerventil für Druckluftbremsen von Schienenfahrzeugen
DE2210633C2 (de) * 1972-03-06 1983-09-22 Bayer Ag, 5090 Leverkusen Kondensierte Pyridinderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
BG17877A1 (et) * 1972-09-26 1974-03-05
FR2265355B1 (et) * 1974-03-28 1977-11-04 Blum Jean
US4105776A (en) * 1976-06-21 1978-08-08 E. R. Squibb & Sons, Inc. Proline derivatives and related compounds
US4339600A (en) * 1976-05-10 1982-07-13 E. R. Squibb & Sons, Inc. Compounds for alleviating angiotensin related hypertension
CA1067079A (en) * 1976-07-22 1979-11-27 Yamanouchi Pharmaceutical Co. Nitrogen-containing heterobicyclic compounds
US4225495A (en) * 1978-12-07 1980-09-30 E. R. Squibb & Sons, Inc. Pyrrolo or pyrido [2,1-c][1,4] thiazines or thiazepines
US4192945A (en) * 1978-12-07 1980-03-11 E. R. Squibb & Sons, Inc. Process for preparing proline and homoproline derivatives
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
IL61972A0 (en) * 1980-01-30 1981-02-27 Beecham Group Ltd Azabicyclic compounds,their preparation and pharmaceutical compositions containing them
US4337201A (en) * 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
US4415496A (en) * 1981-03-23 1983-11-15 Merck & Co., Inc. Bicyclic lactams
US4432972A (en) * 1981-08-03 1984-02-21 E. R. Squibb & Sons, Inc. Phosphonamidate compounds
US4432971A (en) * 1981-08-03 1984-02-21 E. R. Squibb & Sons, Inc. Phosphonamidate compounds
US4873235A (en) * 1982-06-01 1989-10-10 Merck & Co., Inc. Benzofused lactams as antihypertensives
FR2540495B1 (fr) * 1983-02-07 1986-02-14 Roussel Uclaf Nouveaux derives de o-mercaptopropanamide et de ses homologues, leur procede de preparation, leur application comme medicaments, les compositions les renfermant et les nouveaux intermediaires obtenus
US4711884A (en) * 1983-02-28 1987-12-08 E. R. Squibb & Sons, Inc. Thiazine and thiazepine containing compounds
US4460579A (en) * 1983-02-28 1984-07-17 E. R. Squibb & Sons, Inc. Thiazine and thiazepine containing compounds
US4617301A (en) * 1983-06-22 1986-10-14 Merck & Co., Inc. Sulfoxide and sulfone derivatives of bicyclic lactams as antihypertensives
US4722810A (en) * 1984-08-16 1988-02-02 E. R. Squibb & Sons, Inc. Enkephalinase inhibitors
US4584294A (en) * 1984-11-07 1986-04-22 Merck & Co., Inc. Fused tricyclic lactams as angiotensin converting enzyme inhibitors and as antihypertensive agents
US4801609B1 (en) * 1987-03-27 1993-11-09 Mercapto-acylamino acid antihypertensives
US4749688A (en) * 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
EP0254032A3 (en) * 1986-06-20 1990-09-05 Schering Corporation Neutral metalloendopeptidase inhibitors in the treatment of hypertension
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
CA1337400C (en) * 1987-06-08 1995-10-24 Norma G. Delaney Inhibitors of neutral endopeptidase
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US4879309A (en) * 1988-09-27 1989-11-07 Schering Corporation Mercapto-acylamino acids as antihypertensives
US5075302A (en) * 1990-03-09 1991-12-24 Schering Corporation Mercaptoacyl aminolactam endopeptidase inhibitors
FR2664269B1 (fr) * 1990-07-05 1992-10-02 Roussel Uclaf Nouveaux derives n-substitues d'alpha-mercapto alkylamines, leur procede de preparation, leur application a titre de medicaments et les compositions les renfermant.
CA2053340C (en) * 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
US5232920A (en) * 1990-12-21 1993-08-03 Schering Corporation N-(mercaptoalkyl)amides
FR2679564A1 (fr) * 1991-07-23 1993-01-29 Inst Nat Sante Rech Med Nouveaux acylmercaptoalcanoldipeptides, leur preparation et les compositions qui les contiennent.
AU657793B2 (en) * 1991-09-27 1995-03-23 Merrell Pharmaceuticals Inc. Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
DE69220744T2 (de) * 1991-09-27 1997-11-13 Merrell Pharma Inc 2-Substituierte Indan-2-Mercaptoacetylamid-Verbindungen mit Enkephalinase und ACE-Hemmwirkung
ZA927211B (en) * 1991-09-27 1993-03-24 Merrell Dow Pharma Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE.
DK0625987T3 (da) * 1992-02-14 1999-01-11 Merrell Pharma Inc Aminoacetylmercaptoacetylamid-derivater, der kan anvendes som inhibitorer af enkephalinase og ACE
US5552397A (en) * 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
CA2139930A1 (en) 1992-07-10 1994-01-20 Alan Martin Birch Dioxycyclobutene derivatives as angiotensin ii antagonists
NZ254656A (en) * 1992-08-24 1995-12-21 Merrell Dow Pharma Tricyclic benzazepine derivatives; preparation and pharmaceutical compositions
US5208236A (en) * 1992-09-23 1993-05-04 Schering Corporation N-(acylaminomethyl)glutaryl amino acids and use
US5504080A (en) * 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
EP0669936B1 (en) * 1992-10-30 2000-11-22 Merrell Pharmaceuticals Inc. Mercaptoacetylamide bicyclic lactam derivatives useful as inhibitors of enkephalinase and ace
GB9302331D0 (en) * 1993-02-05 1993-03-24 Smithkline Beecham Plc Process
US5508272A (en) * 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
US5362727A (en) * 1993-07-26 1994-11-08 Bristol-Myers Squibb Substituted azepino[2,1-a]isoquinoline compounds
US5525723A (en) * 1993-11-18 1996-06-11 Bristol-Myers Squibb Co. Compounds containing a fused multiple ring lactam

Also Published As

Publication number Publication date
DE69433752T2 (de) 2005-04-21
EP0629627B1 (en) 2004-05-06
FI20000814A (fi) 2000-04-06
CA2124375C (en) 2003-01-28
BG62139B1 (bg) 1999-03-31
LV10622B (en) 1995-10-20
FI111950B (fi) 2003-10-15
IL109924A (en) 1998-09-24
US5627278A (en) 1997-05-06
ZA944163B (en) 1995-02-09
ATE266032T1 (de) 2004-05-15
PH30830A (en) 1997-10-17
RU94021350A (ru) 1996-04-20
UA39924C2 (uk) 2001-07-16
FI111947B (fi) 2003-10-15
MY123673A (en) 2006-05-31
UY23787A1 (es) 1994-12-06
EP0629627A3 (en) 1995-05-17
DE69433752D1 (de) 2004-06-09
AU672899B2 (en) 1996-10-17
EP0629627A2 (en) 1994-12-21
GEP19981301B (en) 1998-05-14
JP3569550B2 (ja) 2004-09-22
US5672599A (en) 1997-09-30
HK1001814A1 (en) 1998-07-10
FI20000815A (fi) 2000-04-06
PL178469B1 (pl) 2000-05-31
PT629627E (pt) 2004-09-30
DK0629627T3 (da) 2004-07-26
US5670699A (en) 1997-09-23
RU2125056C1 (ru) 1999-01-20
JPH0748259A (ja) 1995-02-21
LV10622A (lv) 1995-04-20
SK282529B6 (sk) 2002-10-08
TW329423B (en) 1998-04-11
IL109924A0 (en) 1994-10-07
US5508272A (en) 1996-04-16
RO112870B1 (ro) 1998-01-30
SG46510A1 (en) 1998-02-20
KR950000711A (ko) 1995-01-03
EG20537A (en) 1999-07-31
LTIP1954A (en) 1995-02-27
HU9401776D0 (en) 1994-09-28
BG98854A (bg) 1995-05-31
CY2492B1 (en) 2005-09-02
HUT70842A (en) 1995-11-28
FI106464B (fi) 2001-02-15
NZ260736A (en) 1997-01-29
US5756832A (en) 1998-05-26
CZ289488B6 (cs) 2002-02-13
HU216791B (hu) 1999-08-30
AU6466794A (en) 1994-12-22
CZ140294A3 (en) 1996-08-14
FI942793A (fi) 1994-12-16
CN1099392A (zh) 1995-03-01
CN1046525C (zh) 1999-11-17
NO942208D0 (no) 1994-06-13
BR1100970A (pt) 1999-12-07
KR100395604B1 (ko) 2004-05-10
ES2219644T3 (es) 2004-12-01
LT3626B (en) 1995-12-27
SK72594A3 (en) 1995-05-10
NO306405B1 (no) 1999-11-01
IL120051A0 (en) 1997-04-15
FI942793A0 (fi) 1994-06-13
NO942208L (no) 1994-12-16
PL303832A1 (en) 1995-01-09
CA2124375A1 (en) 1994-12-16

Similar Documents

Publication Publication Date Title
EE03178B1 (et) Kondenseerunud bitsüklilist tuuma sisaldavad ühendid, nende vaheproduktid, valmistamismeetodid ja farmatseutilised kompositsioonid
AU673111B2 (en) Compounds containing a fused multiple ring lactam
ES2101960T3 (es) Lactamas benzo-condensadas.
DE69610873D1 (de) Thiazolobenzazepin-enthaltende Inhibitoren mit zweifacher Wirkung
DK0747392T3 (da) Dobbeltvirkende inhibitorer indeholdende 1,2-diazepiner
NO894349D0 (no) Tienopyridin-type mevalonolaktoner.
DK488588A (da) Sulfonamid-forbindelser, farmaceutiske praeparater indeholdende disse og anvendelse af forbindelserne til fremstilling af antiarytmiske laegemidler
DE68902490T2 (de) Pharmazeutische zusammensetzung.

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20081031